Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. for Securities Fraud

The legal landscape was recently shaken by news of a securities fraud class action lawsuit filed against Ultragenyx Pharmaceutical Inc. This lawsuit, initiated by Kessler Topaz Meltzer & Check, LLP, targeted investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, alleging material misstatements and omissions related to the company’s drug, setrusumab.

Throughout this class period, Ultragenyx was accused of creating a facade of possessing reliable information concerning the effects of setrusumab on patients with various forms of Osteogenesis Imperfecta. The company downplayed risks associated with patients in the Phase III Orbit study failing to achieve a significant reduction in annualized fracture rate necessary for the second interim analysis to move forward publicly. Investors were misled by Ultragenyx’s optimism about the study’s results, based on erroneous benchmarks drawn from Phase II results that lacked a placebo control group for a proper comparison, potentially inflating positive outcomes.

These allegations point to substantial discrepancies between Ultragenyx’s public statements and the reality of its clinical trials, calling into question the company’s business integrity and future prospects. Investors who purchased Ultragenyx common stock during the specified period have until April 6, 2026, to seek lead plaintiff status, allowing them to take legal action on behalf of the entire affected class.

Ultragenyx spokespersons urged investors who experienced losses concerning the company’s stock to reach out to their legal counsel, Kessler Topaz Meltzer & Check, LLP, to evaluate their options for potential financial recovery. Investors can choose to stand as a lead plaintiff by the abovementioned deadline or remain a passive member, letting appointed representatives handle the lawsuit proceedings. Lead plaintiffs are expected to embody the class’s financial interests and select the legal representation to navigate the case.

Kessler Topaz Meltzer & Check, LLP has a track record of handling securities fraud class actions and advocating for investor rights on a global scale. The firm’s expertise and recognition within the legal community underscore its commitment to safeguarding investors’ interests and seeking justice in cases of corporate malfeasance. Investors impacted by the Ultragenyx case are encouraged to contact Kessler Topaz Meltzer & Check, LLP to learn more about their legal options and the process for participating in the ongoing class action lawsuit.